All In Biotech

Drug Trial Radar · NCT00127205

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,097 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,097

Actual

Start

Jul 2005

Primary completion

Dec 2017

Study completion Mar 29, 2021

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; NSABP Foundation Inc; Cancer and Leukemia Group B; NCIC Clinical Trials Group
First posted
Aug 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.

Conditions

  • Breast Cancer

Interventions

  • clodronate disodiumDrug

    Given orally

  • ibandronate sodiumDrug

    Given orally

  • zoledronic acidDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free SurvivalTime frame: Disease assessments are completed every 6 months for 5 years then annually for 5 years or until death or recurrence

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.